Clinical Trial Update: The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating an antioxidant combination (ASTED) for moderate to severe Thyroid Eye Disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• ASTED

Snippet

Sponsor: Iran University of Medical Sciences | Conditions: Thyroid Eye Disease | Phase 2, Phase 3 | Status: WITHDRAWN